EA200501267A1 - Жирные кислоты со средней длиной цепи, глицериды и аналоги в качестве стимуляторов эритропоэза - Google Patents

Жирные кислоты со средней длиной цепи, глицериды и аналоги в качестве стимуляторов эритропоэза

Info

Publication number
EA200501267A1
EA200501267A1 EA200501267A EA200501267A EA200501267A1 EA 200501267 A1 EA200501267 A1 EA 200501267A1 EA 200501267 A EA200501267 A EA 200501267A EA 200501267 A EA200501267 A EA 200501267A EA 200501267 A1 EA200501267 A1 EA 200501267A1
Authority
EA
Eurasian Patent Office
Prior art keywords
erythropoesis
stimulators
glycerides
analogues
fatty acids
Prior art date
Application number
EA200501267A
Other languages
English (en)
Other versions
EA009939B1 (ru
Inventor
Кристофер Пенни
Лин Ганьон
Пьер Лорэн
Було Зашари
Original Assignee
Прометик Байосайенсиз, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Прометик Байосайенсиз, Инк. filed Critical Прометик Байосайенсиз, Инк.
Publication of EA200501267A1 publication Critical patent/EA200501267A1/ru
Publication of EA009939B1 publication Critical patent/EA009939B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Abstract

Применение композиции, содержащей соединение любой из формул I, II, IIa, III и IIIa или их сочетание, где каждый Rнезависимо представляет собой Cалкил; A и B независимо представляют собой H или CO-R; Rпредставляет собой H или Cалкил; M представляет собой монокатион металла (k=1) или дикатион (k=2); Y представляет собой O или NH; и Z представляет собой O, NH, CHO или связь, для производства медикамента для стимуляции эритропоэза. Предпочтительно композиция дополнительно содержит человеческий эритропоэтин.Международная заявка была опубликована вместе с отчетом о международном поиске.
EA200501267A 2003-02-07 2004-02-06 Жирные кислоты со средней длиной цепи, глицериды и аналоги в качестве стимуляторов эритропоэза EA009939B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US44545403P 2003-02-07 2003-02-07
PCT/GB2004/000457 WO2004069237A1 (en) 2003-02-07 2004-02-06 Medium-chain length fatty acids, glycerides and analogues as stimulators of erythropoiesis

Publications (2)

Publication Number Publication Date
EA200501267A1 true EA200501267A1 (ru) 2006-02-24
EA009939B1 EA009939B1 (ru) 2008-04-28

Family

ID=32850990

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200501267A EA009939B1 (ru) 2003-02-07 2004-02-06 Жирные кислоты со средней длиной цепи, глицериды и аналоги в качестве стимуляторов эритропоэза

Country Status (28)

Country Link
US (1) US9682054B2 (ru)
EP (1) EP1592416B1 (ru)
JP (1) JP5390070B2 (ru)
KR (1) KR101120775B1 (ru)
CN (1) CN100427081C (ru)
AP (1) AP2005003367A0 (ru)
AR (1) AR043120A1 (ru)
AT (1) ATE419846T1 (ru)
AU (1) AU2004210193B2 (ru)
BR (1) BRPI0407276A (ru)
CA (1) CA2515160C (ru)
CY (1) CY1108963T1 (ru)
DE (2) DE04708802T1 (ru)
DK (1) DK1592416T3 (ru)
EA (1) EA009939B1 (ru)
ES (1) ES2255467T3 (ru)
IL (1) IL170057A (ru)
JO (1) JO2705B1 (ru)
MA (1) MA27664A1 (ru)
MX (1) MXPA05008382A (ru)
MY (1) MY140913A (ru)
NO (1) NO334085B1 (ru)
NZ (1) NZ541593A (ru)
PT (1) PT1592416E (ru)
SI (1) SI1592416T1 (ru)
TN (1) TNSN05189A1 (ru)
WO (1) WO2004069237A1 (ru)
ZA (1) ZA200506246B (ru)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA007322B1 (ru) 2001-04-18 2006-08-25 Прометик Байосайенсиз, Инк. Жирные кислоты со средней длиной цепи, глицериды и аналоги как факторы, способствующие выживанию и активации нейтрофилов
US20070219131A1 (en) * 2004-04-15 2007-09-20 Ben-Sasson Shmuel A Compositions capable of facilitating penetration across a biological barrier
AU2005329255B2 (en) * 2004-04-15 2010-09-30 Chiasma, Inc. Compositions capable of facilitating penetration across a biological barrier
DK2332977T3 (en) 2004-07-23 2016-02-29 Acceleron Pharma Inc ActRII receptor polypeptides
WO2006024174A1 (en) * 2004-09-03 2006-03-09 Prometic Biosciences Inc. Substituted purinyl derivatives with immunomodulator and chemoprotective activity and use alone or with medium-chain length fatty acids or glycerides
MX2007003967A (es) * 2004-10-01 2008-03-04 Prometic Biosciences Inc Alcoholes grasos con longitud de cadena media como estimuladores de hematopoyesis.
US8071580B2 (en) * 2004-10-01 2011-12-06 Prometic Biosciences Inc. Medium-chain length fatty alcohols as stimulators of hematopoiesis
CA3045808C (en) 2005-11-23 2022-08-16 Acceleron Pharma, Inc. Activin-actriia antagonists and uses for promoting bone growth
US8128933B2 (en) 2005-11-23 2012-03-06 Acceleron Pharma, Inc. Method of promoting bone growth by an anti-activin B antibody
US8895016B2 (en) 2006-12-18 2014-11-25 Acceleron Pharma, Inc. Antagonists of activin-actriia and uses for increasing red blood cell levels
ES2415666T3 (es) 2007-02-01 2013-07-26 Acceleron Pharma, Inc. Composiciones farmacéuticas que comprenden antagonistas de Activina-ActRIIa para uso en la prevención o el tratamiento de metástasis de cáncer de mama o pérdida ósea relacionada con el cáncer de mama
TW201907946A (zh) 2007-02-02 2019-03-01 美商艾瑟勒朗法瑪公司 衍生自ＡｃｔＲＩＩＢ的變體與其用途
EP2484372A1 (en) 2007-02-09 2012-08-08 Acceleron Pharma, Inc. Activin-ActRIIa Antagonists and Uses for Promoting Bone Growth in Cancer Patients
CA2699936A1 (en) 2007-09-18 2009-03-26 Acceleron Pharma Inc. Activin-actriia antagonists and uses for decreasing or inhibiting fsh secretion
MX338513B (es) * 2007-11-02 2016-04-20 Prometic Pharma Smt Ltd Acidos grasos de longitud de cadena mediana y gliceridos como agentes de nefroprotección.
ES2414617T3 (es) * 2007-12-19 2013-07-22 Prometic Biosciences Inc. Ácidos grasos de cadena de longitud media, sales y triglicéridos en combinación con gemcitabina para el tratamiento del cáncer pancreático
US8216997B2 (en) 2008-08-14 2012-07-10 Acceleron Pharma, Inc. Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators
HRP20230761T1 (hr) 2008-08-14 2023-10-13 Acceleron Pharma Inc. Gdf zamke
JP5623406B2 (ja) 2008-09-17 2014-11-12 キアズマ インコーポレイテッド 医薬組成物および関連する送達方法
AU2010258931B2 (en) 2009-06-08 2015-04-23 Acceleron Pharma Inc. Methods for increasing thermogenic adipocytes
US8293881B2 (en) 2009-06-12 2012-10-23 Acceleron Pharma Inc. Isolated nucleic acid encoding a truncated ActRIIB fusion protein
IL287990B (en) * 2009-08-13 2022-07-01 Acceleron Pharma Inc Combined use of gdf traps and erythropoietin receptor activators to increase red blood cell levels
ES2658292T3 (es) 2009-11-17 2018-03-09 Acceleron Pharma, Inc. Proteínas ActRIIB y variantes y usos de las mismas con respecto a la inducción de la utrofina para el tratamiento de la distrofia muscular
EP2638065A4 (en) 2010-11-08 2014-04-09 Acceleron Pharma Inc ACTRIIA BINDING AGENTS AND USES THEREOF
TWI572352B (zh) * 2012-03-01 2017-03-01 波麥堤克藥學Ｓｍｔ有限公司 用於製備具中鏈長度之脂肪酸的三酸甘油酯之方法
WO2014071158A1 (en) 2012-11-02 2014-05-08 Celgene Corporation Activin-actrii antagonists and uses for treating bone and other disorders
CN102973922B (zh) * 2012-12-18 2016-02-03 华东理工大学 一种融合蛋白的应用
CA2951926C (en) 2014-06-13 2023-01-10 Acceleron Pharma, Inc. Methods and compositions for treating ulcers
MA41052A (fr) 2014-10-09 2017-08-15 Celgene Corp Traitement d'une maladie cardiovasculaire à l'aide de pièges de ligands d'actrii
ES2946160T3 (es) 2014-12-03 2023-07-13 Celgene Corp Antagonistas de activina-ActRII y usos para tratar síndrome mielodisplásico
AU2016215350B2 (en) 2015-02-03 2021-11-25 Amryt Endo, Inc. Method of treating diseases
US20170021029A1 (en) * 2015-04-15 2017-01-26 Jeffrey Charles Raber Topical formulations and uses
US11141457B1 (en) 2020-12-28 2021-10-12 Amryt Endo, Inc. Oral octreotide therapy and contraceptive methods

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4871768A (en) 1984-07-12 1989-10-03 New England Deaconess Hospital Corporation Dietary supplement utilizing ω-3/medium chain trigylceride mixtures
US6060459A (en) 1987-10-28 2000-05-09 Pro-Neuron, Inc. Enhancing blood cell count with oxypurine nucleosides
US5011852A (en) 1988-07-25 1991-04-30 Applied Analytical Industries, Inc. Liquid oral pharmaceutical compositions of non-steroidal anti-inflammatory drugs
JP3014119B2 (ja) * 1990-05-28 2000-02-28 雪印乳業株式会社 直腸投与用赤血球造血剤
JP3249147B2 (ja) 1990-06-01 2002-01-21 キリン−アムジエン・インコーポレーテツド 生理活性蛋白含有経口製剤
ATE147976T1 (de) * 1991-01-15 1997-02-15 Hemosphere Inc Protein nanomatrizen und verfahren zur herstellung
JPH05163160A (ja) 1991-12-13 1993-06-29 Snow Brand Milk Prod Co Ltd 免疫低下に伴う感染症の予防及び治療用栄養剤
US5214035A (en) 1992-04-16 1993-05-25 Hoechst-Roussel Agri-Vet Company Thixotropic formulations
US5318781A (en) * 1993-04-06 1994-06-07 Hoffmann-La Roche Inc. Absorption enhancement of antibiotics
US20010003739A1 (en) * 1993-06-24 2001-06-14 Astrazeneca Ab Systemic administration of a therapeutic preparation
US5631219A (en) * 1994-03-08 1997-05-20 Somatogen, Inc. Method of stimulating hematopoiesis with hemoglobin
WO1995030413A1 (fr) 1994-05-10 1995-11-16 The Kitasato Institute Accelerateur de proliferation de cellules souches hematopoietiques
US5470861A (en) 1994-08-04 1995-11-28 Hoffmann-La Roche Inc. Method of promoting hair growth
US5549905A (en) 1994-10-18 1996-08-27 Clintec Nutrition Co. Enternal composition for pediatric patients
IT1275802B1 (it) 1994-11-03 1997-10-17 Hoffmann La Roche Composizione di interferone
GB9516268D0 (en) 1995-08-08 1995-10-11 Danbiosyst Uk Compositiion for enhanced uptake of polar drugs from the colon
AUPN933396A0 (en) 1996-04-17 1996-05-09 Pfizer Pty Limited Non-aqueuos oral-drench compositions containing avermectin compounds
US5851534A (en) 1996-05-03 1998-12-22 Dynagen, Inc. Methods for prevention and/or treatment of neutropenia
JPH10265380A (ja) 1997-03-17 1998-10-06 Bristol Myers Squibb Co 抗ガン剤
WO1999011242A1 (en) * 1997-09-04 1999-03-11 Biozone Laboratories, Inc. Oral liposomal delivery system
EP1030652B1 (en) * 1997-11-14 2012-04-25 Pacira Pharmaceuticals, Inc. Production of multivesicular liposomes
BR9814693B1 (pt) 1997-11-19 2011-04-19 suspensões de polìmero fluidificado de polissacarìdeos catiÈnicos em emolientes e processo para preparação de uma composição para cuidado pessoal.
WO1999026640A1 (en) 1997-11-20 1999-06-03 Bukwang Pharm. Ind. Co., Ltd. Pharmaceutical composition containing extracts of cervus nippon antlers having growth-stimulating activities of hematopoietic stem cells and megakaryocytes
ES2224299T3 (es) * 1998-02-23 2005-03-01 Cilag Ag International Dispersion liposomal de eritroyetina.
JP4372347B2 (ja) 1998-03-11 2009-11-25 あすか製薬株式会社 発泡性腸溶製剤
US6267985B1 (en) 1999-06-30 2001-07-31 Lipocine Inc. Clear oil-containing pharmaceutical compositions
KR20020059415A (ko) 1999-09-27 2002-07-12 스티븐 씨. 큐웨이 토콜-가용성 치료요법제
US6835750B1 (en) 2000-05-01 2004-12-28 Accera, Inc. Use of medium chain triglycerides for the treatment and prevention of alzheimer's disease and other diseases resulting from reduced neuronal metabolism II
DE60123603T2 (de) 2000-06-14 2007-08-16 William Leslie Diss Porter Lipide zur änderung des abwehrsystems
US6967028B2 (en) 2000-07-31 2005-11-22 Mainelab Prolonged release microspheres for injectable administration
IL142535A0 (en) 2001-04-11 2002-03-10 Yeda Res & Dev Pharmaceutical compositions for the treatment of inflammation
EA007322B1 (ru) * 2001-04-18 2006-08-25 Прометик Байосайенсиз, Инк. Жирные кислоты со средней длиной цепи, глицериды и аналоги как факторы, способствующие выживанию и активации нейтрофилов
US20040052836A1 (en) 2002-09-13 2004-03-18 Li Luk Chiu Pharmaceutical compositions containing at least one stable liposphere having an improved shelf life
US6725510B1 (en) 2003-04-25 2004-04-27 Almetta Clyburn Inclining coffin
JP5214880B2 (ja) 2003-07-25 2013-06-19 プロメティック、バイオサイエンシーズ、インコーポレーテッド 中鎖脂肪酸の金属塩の製造
WO2006024174A1 (en) 2004-09-03 2006-03-09 Prometic Biosciences Inc. Substituted purinyl derivatives with immunomodulator and chemoprotective activity and use alone or with medium-chain length fatty acids or glycerides
US8071580B2 (en) 2004-10-01 2011-12-06 Prometic Biosciences Inc. Medium-chain length fatty alcohols as stimulators of hematopoiesis

Also Published As

Publication number Publication date
KR20050118671A (ko) 2005-12-19
DE602004018902D1 (de) 2009-02-26
ZA200506246B (en) 2006-12-27
WO2004069237A1 (en) 2004-08-19
AR043120A1 (es) 2005-07-20
CA2515160C (en) 2013-01-08
EA009939B1 (ru) 2008-04-28
EP1592416A1 (en) 2005-11-09
NZ541593A (en) 2009-05-31
DK1592416T3 (da) 2009-04-20
CY1108963T1 (el) 2014-07-02
PT1592416E (pt) 2009-04-03
IL170057A (en) 2011-09-27
NO20053994L (no) 2005-10-06
BRPI0407276A (pt) 2006-01-31
ES2255467T1 (es) 2006-07-01
SI1592416T1 (sl) 2009-06-30
NO20053994D0 (no) 2005-08-26
DE04708802T1 (de) 2006-06-22
ES2255467T3 (es) 2009-05-01
AP2005003367A0 (en) 2005-09-30
ATE419846T1 (de) 2009-01-15
AU2004210193A1 (en) 2004-08-19
MA27664A1 (fr) 2005-12-01
JO2705B1 (ar) 2014-03-15
US20060128800A1 (en) 2006-06-15
MXPA05008382A (es) 2005-11-04
TNSN05189A1 (en) 2007-06-11
JP2006516987A (ja) 2006-07-13
EP1592416B1 (en) 2009-01-07
AU2004210193B2 (en) 2007-07-12
US9682054B2 (en) 2017-06-20
CN1753665A (zh) 2006-03-29
KR101120775B1 (ko) 2012-04-18
CN100427081C (zh) 2008-10-22
NO334085B1 (no) 2013-12-09
JP5390070B2 (ja) 2014-01-15
CA2515160A1 (en) 2004-08-19
MY140913A (en) 2010-01-29

Similar Documents

Publication Publication Date Title
EA200501267A1 (ru) Жирные кислоты со средней длиной цепи, глицериды и аналоги в качестве стимуляторов эритропоэза
EA200401540A1 (ru) Спироиндолинпиперидиновые производные
NO20062644L (no) DPP-IV inhibitorer
EA200001122A1 (ru) Ингибиторы синтазы оксида азота
RU92016217A (ru) Двойные ингибиторы no синтазы и циклооксигеназы, способ их получения и фармацевтическая композиция на их основе
EA200400892A1 (ru) Производные никотинамида, полезные в качестве ингибиторов pde4
ATE260255T1 (de) 5-oxo-pyrrolidine-2-carbonsäure- hydroxamidderivate
CO5150182A1 (es) Compuestos de triazol y su utilizacion
ATE516321T2 (de) Zusammensetzungen mit fluorosubstituierten olefinen
DE60332350D1 (de) Disazofarbstoffe und sie enthaltende tintenstrahldrucktinten
EP1394154A4 (en) HETEROCYCLIC DERIVATIVE WITH FIVE MEMBERS OF ALKANOIC ACID
AR082075A1 (es) Derivados de dioxima eter microbicidas
EA200500690A1 (ru) Новые соединения пиридопиримидинона, способ их получения и фармацевтические композиции, которые их содержат
EA200500122A1 (ru) Новые соединения, фармацевтические композиции, содержащие их, и способы их использования
EA200400806A1 (ru) Способ получения эхинокандиновых соединений
SE0203300D0 (sv) Novel Compounds
TR24930A (tr) Kuslarin kontrol edilmesinde veya bununla ilgili gelismeler
BR9914122A (pt) Diésteres de ácido carboxìlico alifático como herbicidas não seletivos
AR043186A1 (es) Indozolamidas dotadas de actividad analgesica, metodo de preparacion de las mismas y compuesto farmaceutico que las comprende
EA200300272A1 (ru) Новые производные хиназолина, способ их получения и фармацевтические композиции, содержащие их
EA200500133A1 (ru) Производные пирролидина в качестве антагонистов окситоцина
KR970703301A (ko) 신규 디아미노메틸리덴 유도체(novel diamincmethylidene derivative)
EA200501696A1 (ru) Новые соединения тиадиазина, способ их получения и фармацевтические композиции, которые их содержат
DE69418110D1 (de) N-Heteroaryl substituierte Propanamid-Derivate brauchbar zur Behandlung cardiovascularer Krankheiten
BG106846A (en) Novel heteroaryl derivatives, their preparation and use

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU